菅研究室｜メンバー紹介

Postdoctoral Scholar

City/country of origin: Los Angeles, California, USA
Hobbies: Fashion, makeup, and skincare
Places You Like: Anywhere with a sweet treat or drink
Where for a big vacation: The Maldives or The South of France
What are your strong points?: Creative and adaptable
Music: what is some intense music for intense lab work?: BRAT by Charli XCX and Midnight Sun by Zara Larsson
What are people in the lab doing?: Locking in
What was surprising about the suga lab: It is a very friendly and multicultural environment.
Original motivation towards science?: I like to learn new things and want to have a positive impact on society
A few words for future lab mates: Stay locked in, but also have fun!
Science is…….: challenging, but worth every moment

2020-2025: Ph.D., Department of Chemistry, University of California, Davis
2015-2020: B.S., Department of Chemistry, California State University, Channel Islands

"Synthesis of 2'-O,4'-Calpha-Dimethyl Ribonucleoside Analogs and Their Effects on RNA and Modulation of ADAR Editing.": V. Jauregui-Matos; H.F. Brinkman; P.J. Salvador; O. Jacobs; J. Cheng; S. Mozumder; T. Vu; A.J. Fisher; P.A. Beal; Chemistry, 32, e02958 (2026)
"Discovery and Tuning of RNA Editing Guides via High-Throughput Screening and Chemical Modification.": P.J. Salvador; S. Lin; M.M. Chinn; V. Jauregui-Matos; A. Manjunath; I. Yang; C.S. Jacobsen; P.A. Beal; Chembiochem, 26, e202500735 (2025)
"En masse evaluation of RNA guides (EMERGe) for ADARs.": P.J. Salvador; N.M. Dugan; R. Ouye; P.A. Beal; Methods Enzymol, 710, 131-152 (2025)
"Site-specific regulation of RNA editing with ribose-modified nucleoside analogs in ADAR guide strands.": V. Jauregui-Matos; O. Jacobs; R. Ouye; S. Mozumder; P.J. Salvador; K.D. Fink; P.A. Beal; Nucleic Acids Res, 52, 6733-6747 (2024)
"Library Screening Reveals Sequence Motifs That Enable ADAR2 Editing at Recalcitrant Sites.": C.S. Jacobsen; P. Salvador; J.F. Yung; S. Kragness; H.G. Mendoza; G. Mandel; P.A. Beal; ACS Chem Biol, 18, 2188-2199 (2023)
"Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1).": P.J. Salvador; H.B. Jacobs; L. Alnouri; A. Fee; L.M. Utley; M. Mabry; H. Krajeck; C. Dicksion; A.M. Awad; Med Chem Res, 31, 1109-1119 (2022)